文献速递药物相互作用药物不良反应与药物警戒

AZD4635在健康受试者中的综合临床药理学特征:支持剂量考虑

Comprehensive clinical pharmacology characterization of AZD4635 in healthy participants to support dosing considerations.
PubMed 文献 · Br J Clin Pharmacol · 2023-05-22

两项1期研究评估了AZD4635的口服生物利用度及食物、吸烟、质子泵抑制剂(PPI)和CYP1A2抑制剂对其药代动力学的影响。结果显示高脂餐降低吸收速率但不影响程度,PPI无影响,吸烟无影响,而氟伏沙明显著增加暴露并延长半衰期。所有方案耐受良好。

要点

  • 高脂餐使AZD4635胶囊Cmax降低≥50%并延迟吸收,但AUCinf仅降低12%。
  • PPI不影响AZD4635口服生物利用度,吸烟对AZD4635暴露无影响。
  • 氟伏沙明使AZD4635 AUCinf增加约5倍,Cmax增加2倍,半衰期延长至约22小时。

核心结论

  • 高脂餐降低AZD4635吸收速率但不降低吸收程度,胃pH对其影响极小。
  • 吸烟不影响AZD4635的Cmax和AUCinf,氟伏沙明显著增加AZD4635的Cmax和总暴露。
  • 未发现新的安全性问题,所有治疗方案耐受良好。

研究设计与样本

  • 研究1为比较药代动力学研究,纳入非吸烟者(N=21),Part A比较50 mg纳米混悬剂与胶囊(空腹),Part B评估高脂餐或PPI对50 mg胶囊的影响。
  • 研究2为CYP1A2介导的药物相互作用研究,纳入吸烟者和非吸烟者(N=28),给予25 mg AZD4635胶囊(空腹)伴或不伴100 mg氟伏沙明。

主要发现

  • 研究1中胶囊与纳米混悬剂的AZD4635暴露相当。
  • 高脂餐使胶囊AUCinf降低12%,Cmax降低≥50%,Tmax延迟(4.0 h vs 1.5 h)。
  • PPI不影响AZD4635胶囊的口服生物利用度。
  • 研究2中,与单用AZD4635相比,AZD4635+氟伏沙明使吸烟者AUCinf增加约5倍、Cmax增加2倍,半衰期从9.0 h延长至22.7 h;非吸烟者AUCinf增加约5倍、Cmax增加2倍,半衰期从9.2 h延长至22.4 h。
  • 最常见不良事件包括头晕、恶心和头痛。

临床怎么用

  • 临床使用AZD4635时应考虑高脂餐对吸收速率的影响,但吸收程度不受显著影响。
  • 合并使用CYP1A2强抑制剂(如氟伏沙明)时需警惕AZD4635暴露显著增加。
  • 吸烟状态对AZD4635暴露无显著影响,无需据此调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Two phase 1 studies characterized the oral bioavailability of AZD4635 (potential anticancer therapy) and factors that may influence its pharmacokinetics (PKs; food, smoking, proton-pump inhibitors [PPIs] and CYP1A2 inhibitors) to support continued clinical development of AZD4635. METHODS: Study 1 (comparative PK study; nonsmokers) consists of Part A and Part B. Participants (fasted) in Part A were administered 50 mg of AZD4635 either as nanosuspension or capsule. In Part B, these participants were administered a 50-mg capsule either following a high-fat meal or with a PPI in the fasted state. In Study 2 (CYP1A2 mediated drug-drug interaction study), a 25-mg AZD4635 capsule was administered to smokers and nonsmokers (fasted) with or without 100 mg of fluvoxamine. RESULTS: In Study 1 (N = 21), AZD4635 exposure was comparable between the capsule and nanosuspension. The high-fat meal produced a 12% decrease in AUCinf , a ≥50% reduction in Cmax and delayed absorption (Tmax : 4.0 h vs 1.5 h) for the capsule. The PPI did not affect the oral bioavailability of the AZD4635 capsule. In Study 2 (N = 28), AZD4635 + fluvoxamine (compared with AZD4635 alone) produced ~5-fold increases in AUCinf , 2-fold increases in Cmax and prolonged AZD4635 elimination half-life in smokers (22.7 vs 9.0 h) and nonsmokers (22.4 vs 9.2 h). All treatment regimens were well tolerated. The most common adverse events included dizziness, nausea and headache. CONCLUSIONS: The high-fat meal reduced the rate but not the extent of AZD4635 absorption. The effect of gastric pH on AZD4635 was minimal. Smoking had no effect on the exposure (Cmax and AUCinf ) of AZD4635, while fluvoxamine increased AZD4635 Cmax and total exposure. No new safety concerns were identified.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Moorthy G, Pouliot GP, Graham L, et al. Comprehensive clinical pharmacology characterization of AZD4635 in healthy participants to support dosing considerations. Br J Clin Pharmacol. 2023. PMID: 37055936. doi:10.1111/bcp.15742

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。